Lille, France – 02/08/2021: HCS Pharma, announced today that it has signed an agreement with GEM Global Yield LLC SCS ("GEM") a Luxemburg-based private alternative investment group for a EUR 20 million capital commitment.
European high-tech companies raise just a fraction of the amount of their U.S. and Chinese competitors. InvestHorizon is a 3-year programme which intends to address this gap in the market and provide services designed to facilitate access to Series A funding and boost investment readiness and investor relations.
This project has been funded with support from the European Commission. This publication reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein.
We also use analytics services to help us understand where our audience is coming from. To opt-out click 'More information'.